QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
Dr. Catalona has written articles and answered questions on the topic of hormonal therapy in previous issues of QUEST, but new therapies are rapidly becoming available, and previous articles are no longer up-to-date. This article provides information on and an…
Collaboration of SPORE Genetics and Active Surveillance Working Groups on Developing Genetic Markers Useful for Selecting Treatment of Prostate Cancer One of the most important questions currently facing prostate cancer practitioners is: How can we know which men diagnosed with…
Wheeler Chapman is a numbers man with an analytical background. He’s the founder, president and chief investment officer of Integrated Financial Management, an investment management firm. And he has both bachelor’s and master’s degrees in civil engineering. But it was…
At the annual meeting of the American Urological Association, Dr. Catalona* presents a prostate cancer update for the year that summarizes significant findings from studies published in peer-reviewed medical journals. QUEST is adapting some information from his 2012 presentation to…
Men diagnosed with hormone sensitive metastatic prostate cancer are offered ADT, androgen-deprivation therapy (also called hormone therapy), to slow the progression of the cancer. They are prescribed this therapy, most commonly, after both a radical prostatectomy and radiation (including external…
In 2011, the New England Journal of Medicine published updated results on a Scandinavian Study* reporting on: Radical Prostatectomy Versus Watchful Waiting in Early Prostate Cancer. The article concluded that, overall, compared to men managed with watchful waiting, men treated…
It’s been a long wait, but the FDA (U.S. Food and Drug Administration) has announced approval for Phi* (Prostate Health Index), a simple, non-invasive blood test that is 2.5 times more specific in detecting prostate cancer than PSA in patients…
William J. Catalona, MD; Anthony V. D’Amico, MD; William F. Fitzgibbons, MD; Omofolasade Kosoko-Lasaki, MD; Stephen W. Leslie, MD; Henry T. Lynch, MD; Judd W. Moul, MD; Marc S. Rendell, MD; and Patrick C. Walsh, MD The U.S. Preventive Services…
Brian Helfand; MD, PhD presenting at the recent American Urological Association meeting. At present, while PSA is the best diagnostic tool for early diagnosis of prostate cancer, it is not perfect for cancer detection. Benign conditions also can cause an…
New studies* on PSA Velocity (PSAV) suggest that PSAV risk count, the number of times PSAV exceeds a specific threshold, could increase the reliability of screening for prostate cancer and of screening potentially for life-threatening tumors. PSA Velocity is the…
"*" indicates required fields
